Activation of the GABAB receptor prevents nicotine-induced locomotor stimulation in mice

Frontiers in Psychiatry

Volumn 2, Issue DEC, 2011, Pages

  Lobina, Carla ^a   Carai, Mauro A M ^a   Froestl, Wolfgang ^b   Mugnaini, Claudia ^c   Pasquini, Serena ^c   Corelli, Federico ^c   Gessa, Gian Luigi ^a   Colombo, Giancarlo ^a  

^a CNR   (Italy)

^b AC IMMUNE SA   (Switzerland)

^c UNIVERSITY OF SIENA   (Italy)

Author keywords

Baclofen; CGP7930; GABAB receptor; GS39783; Mouse; Nicotine induced hyperlocomotion; Positive allosteric modulation of the GABAB receptor

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR; BACLOFEN; CPG 7930; DRUGS USED IN THE TREATMENT OF ADDICTION; N,N' DICYCLOPENTYL 2 METHYLTHIO 5 NITRO 4,6 PYRIMIDINEDIAMINE; NICOTINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EVOKED RESPONSE; GABAERGIC SYSTEM; LOCOMOTION; MALE; MOTION ANALYSIS SYSTEM; MOTOR PERFORMANCE; MOUSE; NERVE STIMULATION; NEUROMODULATION; NONHUMAN; PSYCHOMOTOR ACTIVITY;

EID: 84866883858     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2011.00076     Document Type: Article

References (41)

1. Addolorato, G., and Leggio, L. (2010). Safety and efficacy of baclofen in the treatment of alcohol-dependent patients. Curr. Pharm. Des. 16, 2113-2117.
2. Bowery, N. G., Hudson, A. L., and Price, G. W. (1987). GABAA and GABAB receptor site distribution in the rat central nervous system. Neuroscience 20, 365-383.
3. Corrigall, W. A., Coen, K. M., Adamson, K. L., Chow, B. L., and Zhang, J. (2000). Responseof nicotine self-administration in the rat to manipulations of mu-opioid and γ-aminobutyric acid receptors in the ventral tegmental area. Psychopharmacology (Berl.) 149, 107-114.
4. Corrigall, W. A., Coen, K. M., Zhang, J., and Adamson, K. L. (2001). GABA mechanisms in the peduncu-lopontine tegmental nucleus influence particular aspects of nicotine self-administration selectively in the rat. Psychopharmacology (Berl.) 158, 190-197.
5. Cousins, M. S., Stamat, H. M., and de Wit, H. (2001). Effects of a single dose of baclofen on self-reported subjective effects and tobacco smoking. Nicotine Tob. Res. 3, 123-129.
6. Cryan, J. F., Kelly, P. H., Chaperon, F., Gentsch, C., Mombereau, C., Lingenhoehl, K., Froestl, W., Bettler, B., Kaupmann, K., and Spooren, W. P. (2004). Behavioral characterization of the novel GABAB receptor-positive modulator GS39783 (N, N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine): anxiolytic-like activity without side effects associated with baclofen or benzodiazepines. J. Pharmacol. Exp. Ther. 310, 952-963.
7. Di Chiara, G. (2000). Role of dopamine in the behavioural actions of nicotine related to addiction. Eur. J. Pharmacol. 393, 295-314.
8. Fattore, L., Cossu, G., Martellotta, M. C., and Fratta, W. (2002). Baclofen antagonizes intravenous self-administration of nicotine in mice and rats. Alcohol Alcohol. 37, 495-498.
9. Fattore, L., Spano, M. S., Cossu, G., Scherma, M., Fratta, W., and Fadda, P. (2009). Baclofen prevents drug-induced reinstatement of extinguished nicotine-seeking behaviour and nicotine place preference in rodents. Eur. Neuropsychopharma-col. 19, 487-498.
10. Franklin, T. R., Harper, D., Kamp-man, K., Kildea-McCrea, S., Jens, W., Lynch, K. G., O'Brien, C. P., and Childress, A. R. (2009). The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study. Drug Alcohol Depend. 103, 30-36.
11. Freeman, G. B., Sherman, K. A., and Gibson, G. E. (1987). Locomotor activity as a predictor of times and dosages for studies of nicotine's neurochemical actions. Pharmacol. Biochem. Behav. 26, 305-312.
12. Froestl, W. (2010). Chemistry and pharmacology of GABAB receptor lig-ands. Adv. Pharmacol. 58, 19-62.
13. Hendry, J. S., and Rosecrans, J. A. (1982). Effects of nicotine on conditioned and unconditioned behaviors in experimental animals. Pharmacol. Ther. 17, 431-454.
14. Holstein, S. E., Dobbs, L., and Phillips, T. J. (2009). Attenuation of the stimulant response to ethanol is associated with enhanced ataxia for a GABAA, but not a GABAB, receptor agonist. Alcohol. Clin. Exp. Res. 33, 108-120.
15. Jerlhag, E., and Engel, J. A. (2011). Ghre-lin receptor antagonism attenuates nicotine-induced locomotor stimulation, accumbal dopamine release and conditioned place preference in mice. Drug Alcohol Depend. 117, 126-131.
16. Kalivas, P. W., Duffy, P., and Eber-hardt, H. (1990). Modulation of A10 dopamine neurons by gamma-aminobutyric acid agonists. J. Pharmacol. Exp. Ther. 253, 858-866.
17. Kim, H. S., and Kim, K. S. (1999). Inhibitory effects of ginseng total saponin on nicotine-induced hyperactivity, reverse tolerance and dopamine receptor supersensitivity. Behav. Brain Res. 103, 55-61.
18. Kita, T., Nakashima, T., Shirase, M., Asahina, M., and Kurogochi, Y. (1988). Effects of nicotine on ambulatory activity in mice. Jpn. J. Pharmacol. 46, 141-146.
19. Laviolette, S. R., and van der Kooy, D. (2004). The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. Nat. Rev. Neurosci. 5, 55-65.
20. Le Foll, B., Wertheim, C. E., and Goldberg, S. R. (2008). Effects of baclofen on conditioned rewarding and discriminative stimulus effects of nicotine in rats. Neurosci. Lett. 443, 236-240.
21. Leite-Morris, K. A., Fukudome, E. Y., and Kaplan, G. B. (2002). Opiate-induced motor stimulation is regulated by γ-aminobutyric acid type B receptors found in the ventral tegmental area in mice. Neurosci. Lett. 317, 119-122.
22. Lhuillier, L., Mombereau, C., Cryan, J. F., and Kaupmann, K. (2007). GABAB receptor-positive modulation decreases selective molecular and behavioral effects of cocaine. Neuropsychopharmacology 32, 388-398.
23. Maccioni, P., Fantini, N., Froestl, W., Carai, M. A. M., Gessa, G. L., and Colombo, G. (2008). Specific reduction of alcohol's motivational properties by the positive allosteric modulator of the GABAB receptor, GS39783 - comparison with the effect of the GABAB receptor direct agonist, baclofen. Alcohol. Clin. Exp. Res. 32, 1558-1564.
24. Mansvelder, H. D., and McGehee, D. S. (2002). Cellular and synaptic mechanisms of nicotine addiction. J. Neu-robiol. 53, 606-617.
25. Mombereau, C., Lhuillier, L., Kaup-mann, K., and Cryan, J. F. (2007). GABAB receptor-positive modulation-induced blockade of the rewarding properties of nicotine is associated with a reducti on in nucleus accumbens ΔFosB accumulation. J. Pharmacol. Exp. Ther. 321, 172-177.
26. Paterson, N. E., Bruijnzeel, A. W., Kenny, P. J., Wright, C. D., Froestl, W., and Markou, A. (2005a). Prolonged nicotine exposure does not alter GABAB receptor-mediated regulation of brain reward function. Neu-ropharmacology 49, 953-962.
27. Paterson, N. E., Froestl, W., and Markou, A. (2005b). Repeated administration of the GABAB receptor agonist CGP44532 decreased nicotine self-administration, and acute administration decreased cue-induced reinstatement of nicotine-seeking in rats. Neuropsychopharma-cology 30, 119-128.
28. Paterson, N. E., Froestl, W., and Markou, A. (2004). The GABAB receptor agonists baclofen and CGP44532 decreased nicotine self-administration in the rat. Psychopharmacology (Berl.) 172, 179-186.
29. Paterson, N. E., Vlachou, S., Guery, S., Kaupmann, K., Froestl, W., and Markou, A. (2008). Positive modulation of GABAB receptors decreased nicotine self-administration and counteracted nicotine induced enhancement of brain reward function in rats. J. Pharmacol. Exp. Ther. 326, 306-314.
30. Phillips, T. J., and Shen, E. H. (1996). Neurochemical bases of locomotion and ethanol stimulant effects. Int. Rev. Neurobiol. 39, 243-282.
31. Phillis, B. D., Ong, J., White, J. M., and Bonnielle, C. (2001). Modification of d-amphetamine-induced responses by baclofen in rats. Psychopharmacology (Berl.) 153, 277-284.
32. Quintanilla, M. E., Perez, E., and Tampier, L. (2008). Baclofen reduces ethanol intake in high-alcohol-drinking University of Chile bibulous rats. Addict. Biol. 13, 326-336.
33. Tyacke, R. J., Lingford-Hughes, A., Reed, L. J., and Nutt, D. J. (2010). GABAB receptors in addiction and its treatment. Adv. Pharmacol. 58, 373-396.
34. Urwyler, S. (2011). Allosteric modulation of family C G-protein-coupled receptors: from molecular insights to therapeutic perspectives. Pharmacol. Rev. 63, 59-126.
35. Vlachou, S., Guery, S., Froestl, W., Banerjee, D., Benedict, J., Finn, M. G., and Markou, A. (2011). Repeated administration of the GABAB receptor positive modulator BHF177 decreased nicotine self-administration, and acute administration decreased cue-induced reinstatement of nicotine seeking in rats. Psychopharmacology (Berl.) 215, 117-128.
36. Vlachou, S., and Markou, A. (2010). GABAB receptors in reward processes. Adv. Pharmacol. 58, 315-371.
37. Westerink, B. H., Kwint, H. F., and deVries, J. B. (1996). The pharmacology of mesolimbic dopamine neurons: a dual-probe microdialysis study in the ventral tegmental area and nucleus accumbens of the rat brain. J. Neurosci. 16, 2605-2611.
38. Wise, R. A., and Bozarth, M. A. (1987). A psychomotor stimulant theory of addiction. Psychol. Rev. 94, 469-492.
39. Woo, S. H., Kim, H. S., Yun, J. S., Lee, M. K., Oh, K. W., Seong, Y. H., Oh, S. K., and Jang, C. G. (2001). Inhibition of baclofen on morphine-induced hyperactivity, reverse tolerance and postsynaptic dopamine receptor supersensitivity. Pharmacol. Res. 43, 335-340.
40. Xi, Z. X., and Stein, E. A. (1998). Nucleus accumbensdopamine release modulation by mesolimbic GABAA receptors - an in vivo electrochemical study. Brain Res. 798, 156-165.
41. Yoshida, M., Yokoo, H., Tanaka, T., Emoto, H., and Tanaka, M. (1994). Opposite changes in the mesolim-bic metabolism in the nerve terminal and cell body sites induced by locally infused in the rat. Brain Res. 636, 111-114.